Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enavogliflozin Add-on to Metformin in T2DM
NCT05505994Phase 3Active, not recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Sep 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of enavogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Change from baseline in Hemoglobin A1c at 24 weeks. Started Sep 2022; status: active, not recruiting.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05505994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05505994.